Byrne Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Byrne Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2	Hold	1	–	–	﹤0.01%	620
2026 Q2	$4	Hold	1	–	–	﹤0.01%	587
2026 Q1	$3	Hold	1	–	–	﹤0.01%	565
2025 Q4	$2	Buy	+1	New	+$2	﹤0.01%	559

Other funds holding ELDN

EFG

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Planning Strategies Lancaster, Pennsylvania $169M AUM

Byrne Asset Management's ELDN Position: Q3 2026 in Review

Byrne Asset Management held its Eledon Pharmaceuticals (ELDN) position steady in Q3 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #620.

Byrne Asset Management first reported a position in ELDN in Q4 2025 and has held it in 4 quarters since. The position peaked at $4 in Q2 2026. 7 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

Byrne Asset Management held 1 share of Eledon Pharmaceuticals worth $2 as of Q3 2026.
Byrne Asset Management left its Eledon Pharmaceuticals share count unchanged in Q3 2026.
Eledon Pharmaceuticals made up ﹤0.01% of Byrne Asset Management's portfolio in Q3 2026, its #620 holding.
Byrne Asset Management first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
Byrne Asset Management's Eledon Pharmaceuticals position peaked at $4 in Q2 2026.
7 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Byrne Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.